# Study of the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Participants With Tardive Dyskinesia

> **NCT05859698** · PHASE4 · COMPLETED · sponsor: **Neurocrine Biosciences** · enrollment: 59 (actual)

## Conditions studied

- Schizophrenia
- Schizoaffective Disorder
- Bipolar Disorder
- Major Depressive Disorder
- Tardive Dyskinesia

## Interventions

- **DRUG:** Valbenazine

## Key facts

- **NCT ID:** NCT05859698
- **Lead sponsor:** Neurocrine Biosciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-05-09
- **Primary completion:** 2024-12-27
- **Final completion:** 2024-12-27
- **Target enrollment:** 59 (ACTUAL)
- **Last updated:** 2026-01-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05859698

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05859698, "Study of the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Participants With Tardive Dyskinesia". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05859698. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*